JP2022068180A5 - - Google Patents

Download PDF

Info

Publication number
JP2022068180A5
JP2022068180A5 JP2022011177A JP2022011177A JP2022068180A5 JP 2022068180 A5 JP2022068180 A5 JP 2022068180A5 JP 2022011177 A JP2022011177 A JP 2022011177A JP 2022011177 A JP2022011177 A JP 2022011177A JP 2022068180 A5 JP2022068180 A5 JP 2022068180A5
Authority
JP
Japan
Prior art keywords
uricase
pharmaceutical composition
administered
synthetic nanocarriers
gout
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022011177A
Other languages
English (en)
Japanese (ja)
Other versions
JP7547402B2 (ja
JP2022068180A (ja
Filing date
Publication date
Priority claimed from JP2018548079A external-priority patent/JP7417354B2/ja
Application filed filed Critical
Publication of JP2022068180A publication Critical patent/JP2022068180A/ja
Publication of JP2022068180A5 publication Critical patent/JP2022068180A5/ja
Priority to JP2024065367A priority Critical patent/JP2024102099A/ja
Application granted granted Critical
Publication of JP7547402B2 publication Critical patent/JP7547402B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022011177A 2016-03-11 2022-01-27 ペグ化ウリカーゼの処方物および用量 Active JP7547402B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024065367A JP2024102099A (ja) 2016-03-11 2024-04-15 ペグ化ウリカーゼの処方物および用量

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201662307412P 2016-03-11 2016-03-11
US62/307,412 2016-03-11
US201662339944P 2016-05-22 2016-05-22
US62/339,944 2016-05-22
US201662346348P 2016-06-06 2016-06-06
US62/346,348 2016-06-06
US201662397832P 2016-09-21 2016-09-21
US62/397,832 2016-09-21
US201662398422P 2016-09-22 2016-09-22
US62/398,422 2016-09-22
US201662403664P 2016-10-03 2016-10-03
US62/403,664 2016-10-03
US201662430547P 2016-12-06 2016-12-06
US62/430,547 2016-12-06
US201762442948P 2017-01-05 2017-01-05
US62/442,948 2017-01-05
JP2018548079A JP7417354B2 (ja) 2016-03-11 2017-03-11 ペグ化ウリカーゼの処方物および用量
PCT/US2017/021991 WO2017156513A1 (en) 2016-03-11 2017-03-11 Formulations and doses of pegylated uricase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018548079A Division JP7417354B2 (ja) 2016-03-11 2017-03-11 ペグ化ウリカーゼの処方物および用量

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024065367A Division JP2024102099A (ja) 2016-03-11 2024-04-15 ペグ化ウリカーゼの処方物および用量

Publications (3)

Publication Number Publication Date
JP2022068180A JP2022068180A (ja) 2022-05-09
JP2022068180A5 true JP2022068180A5 (https=) 2022-07-04
JP7547402B2 JP7547402B2 (ja) 2024-09-09

Family

ID=58464628

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018548079A Active JP7417354B2 (ja) 2016-03-11 2017-03-11 ペグ化ウリカーゼの処方物および用量
JP2022011177A Active JP7547402B2 (ja) 2016-03-11 2022-01-27 ペグ化ウリカーゼの処方物および用量
JP2024065367A Pending JP2024102099A (ja) 2016-03-11 2024-04-15 ペグ化ウリカーゼの処方物および用量

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018548079A Active JP7417354B2 (ja) 2016-03-11 2017-03-11 ペグ化ウリカーゼの処方物および用量

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024065367A Pending JP2024102099A (ja) 2016-03-11 2024-04-15 ペグ化ウリカーゼの処方物および用量

Country Status (21)

Country Link
US (3) US20170258927A1 (https=)
EP (2) EP4445955A3 (https=)
JP (3) JP7417354B2 (https=)
KR (3) KR20180120753A (https=)
CN (1) CN109152819A (https=)
AU (2) AU2017230891B2 (https=)
BR (1) BR112018068249A2 (https=)
CA (1) CA3017365A1 (https=)
DK (1) DK3426285T3 (https=)
ES (1) ES2986077T3 (https=)
FI (1) FI3426285T3 (https=)
HR (1) HRP20241127T1 (https=)
HU (1) HUE068144T2 (https=)
IL (2) IL318183A (https=)
LT (1) LT3426285T (https=)
MX (1) MX2018011012A (https=)
PL (1) PL3426285T3 (https=)
PT (1) PT3426285T (https=)
RS (1) RS65941B1 (https=)
SI (1) SI3426285T1 (https=)
WO (1) WO2017156513A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG161247A1 (en) 2005-04-11 2010-05-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
BR122020023215B1 (pt) 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
KR20180120753A (ko) * 2016-03-11 2018-11-06 셀렉타 바이오사이언시즈, 인크. Peg화 우리카제의 제제 및 용량
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
AU2018297309A1 (en) 2017-07-07 2020-01-30 Allena Pharmaceuticals, Inc. Recombinant uricase enzyme
CN109875988B (zh) * 2018-09-13 2021-08-27 江西中医药大学 一种化合物dhnb缩氨基脲的合成及其在防治痛风与高尿酸血症的应用
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
KR102260478B1 (ko) * 2019-08-19 2021-06-02 연세대학교 산학협력단 일나트륨 요소화물 결정 용해용 조성물
EP4021482A4 (en) * 2019-08-30 2023-04-19 Horizon Therapeutics Ireland Dac PEGLOTICASE FOR THE TREATMENT OF GOUT IN KIDNEY TRANSPLANT RECIPIENT
EP4048269A1 (en) * 2019-10-21 2022-08-31 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
CN118384281A (zh) * 2019-11-08 2024-07-26 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
KR102200329B1 (ko) * 2019-11-11 2021-01-08 광주과학기술원 반감기 증가를 위한 치료용 단백질-지방산 접합체 및 이의 용도
EP4588513A3 (en) * 2020-08-10 2025-10-22 Horizon Therapeutics USA, Inc. Methods of treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers
WO2025076412A1 (en) * 2023-10-04 2025-04-10 Gro Biosciences Inc. Modified polypeptides and methods of making and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
JP3462313B2 (ja) 1995-08-24 2003-11-05 キッコーマン株式会社 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体dna及び変異型ウリカーゼの製造法
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
JP4751556B2 (ja) 2000-02-28 2011-08-17 ジーンシーグス, インコーポレイテッド ナノカプセルカプセル化システムおよび方法
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
WO2003020797A1 (en) 2001-08-30 2003-03-13 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
MXPA06006738A (es) 2003-12-19 2006-08-31 Univ North Carolina Metodos para fabricar micro- y nano-estructuras aisladas utilizando litografia suave o de impresion.
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
MX374963B (es) * 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
BR122020023215B1 (pt) * 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
AU2014262164B2 (en) * 2013-05-03 2020-02-27 Selecta Biosciences, Inc. Dosing combinations for reducing undesired humoral immune responses
KR102601922B1 (ko) 2014-11-05 2023-11-15 셀렉타 바이오사이언시즈, 인크. 안정한 과-포화 상태로 라파마이신을 포함하는 합성 나노담체와 관련된 방법 및 조성물
KR20180120753A (ko) * 2016-03-11 2018-11-06 셀렉타 바이오사이언시즈, 인크. Peg화 우리카제의 제제 및 용량

Similar Documents

Publication Publication Date Title
JP2022068180A5 (https=)
JP2024102099A5 (https=)
JP2019507797A5 (https=)
FI3426285T3 (fi) Pegyloidun urikaasin formulaatioita ja annoksia
US20230414521A1 (en) Sustained-release formulations of colchicine and methods of using same
JP2020510687A5 (https=)
US20210030680A1 (en) Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer
JP5890780B2 (ja) 中枢を介する悪心および嘔吐を治療するための組成物および方法
KR20150040338A (ko) 다발경화증 치료용 조합 요법
CN101511348B (zh) 含有包封他汀类之纳米颗粒的药物组合物
KR101925671B1 (ko) 데페라시록스의 경구 제제
US10695299B2 (en) Disulfiram formulation
JP2022535121A5 (https=)
CN106604750A (zh) 治疗骨髓瘤
KR20150002886A (ko) 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
JP2019501881A5 (https=)
JP2023501457A5 (https=)
CN118384281A (zh) 聚乙二醇化尿酸酶的制剂和剂量
JP5404625B2 (ja) 組成物
US11504365B2 (en) Use of tivozanib to treat subjects with refractory cancer
US20180368458A1 (en) Time release vitamins and minerals in edible oils
CA2985379A1 (en) Micronized pharmaceutical compositions for treatment of angiogenisis conditions
US20110117070A1 (en) Compositions and methods for treating headache
JP2019517490A (ja) がん療法のためのメトロノミック経口ゲムシタビン
RU2021136782A (ru) Композиции и дозы пегилированной уриказы